The pharmaceutical industry trade group hopes to convince you that it is not all bark and no bite.
In response to the outcry over Marathon Pharmaceuticals, which plans to sell a decades-old drug for $89,000 and also maintain a monopoly, the Pharmaceutical Research and Manufacturers of America slammed the company for “actions [that] are not consistent with the mission of our organization.” And the group promised a “comprehensive review” of its membership criteria.
About the Author Reprints
What a joke. Cat calling the kettle black.